Filtered By:
Condition: Dementia
Management: Medicare
This page shows you your search results in order of date.
Order by Relevance | Date
Total 73 results found since Jan 2013.
Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease.
6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources.
[time-brightcove not-tgx=”true”]
...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news
Hierarchical Development of Physical Frailty and Cognitive Impairment and Their Association With Incident Cardiovascular Disease
CONCLUSIONS: The simultaneous development of frailty and CI is associated with an increased risk of adverse cardiovascular outcomes including death compared with the development of each syndrome alone. Diagnostics to detect frailty and CI are critical in assessment of cardiovascular risk in the older population.PMID:37538136 | PMC:PMC10399211 | DOI:10.1016/j.jacadv.2023.100318
Source: Adv Data - August 4, 2023 Category: Epidemiology Authors: Abdulla A Damluji Naila Ijaz Shang-En Chung Qian-Li Xue Rani K Hasan Wayne B Batchelor Ariela R Orkaby Ajar Kochar Michael G Nanna David L Roth Jeremy D Walston Jon R Resar Gary Gerstenblith Source Type: research
Association of Plasma A β 42/40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities Study
DISCUSSION: A reduction in plasma Aβ42/Aβ40 is associated with an increased risk of subsequent epilepsy. Our observations provide a further validation of the link between Aβ, hyperexcitable states, and LOE.PMID:37541842 | DOI:10.1212/WNL.0000000000207635
Source: Atherosclerosis - August 4, 2023 Category: Cardiology Authors: Emily L Johnson Kevin J Sullivan Andrea Lauren Christman Schneider Jeannette Simino Tom H Mosley Anna Kucharska-Newton David S Knopman Rebecca F Gottesman Source Type: research
2023 Alzheimer's disease facts and figures
This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report examines the patient journey from awareness of cognitive changes to potential treatment with drugs that change the underlying biology of Alzheimer's. An estimated 6.7 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Off...
Source: The Journal of Alzheimers Association - March 15, 2023 Category: Psychiatry Source Type: research
Effects of Patient Comorbidities and Demographics on Episode-of-Care Costs Following Total Shoulder Arthroplasty
CONCLUSION: Providers should be aware that certain demographic variables and comorbidities (history of stroke, dementia, chronic pulmonary disease, anemia, heart disease, advanced age, and elevated body mass index) are associated with an increase in total costs following primary shoulder arthroplasty. Further study is required to determine whether bundled payment target costs should be adjusted to better compensate for specific comorbidities.LEVEL OF EVIDENCE: Level IV case series.PMID:36749879 | DOI:10.5435/JAAOS-D-22-00450
Source: The Journal of the American Academy of Orthopaedic Surgeons - February 7, 2023 Category: Orthopaedics Authors: Dominic M Farronato Joshua D Pezzulo Alexander J Rondon Sean Porrini Diane McGonigal Charles L Getz Daniel E Davis Source Type: research
FDA Approves Lecanemab, a New Alzheimer ’s Drug
On Jan. 6, the U.S. Food and Drug Administration (FDA) approved a new drug to treat Alzheimer’s disease in its early stages.
Lecanemab, which will be available under the name Leqembi, can slow the cognitive decline associated with Alzheimer’s disease by 27%, according to data submitted to the FDA by the drug’s developers, Eisai and Biogen. It’s only the second medication to show any improvement in neurodegeneration, a key criterion in the FDA’s consideration for approval.
“For a long time, this is what we have been looking for,” says Dr. Sam Gandy, professor of neurology and psychi...
Source: TIME: Health - January 6, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Drugs healthscienceclimate Source Type: news
As some hail new antibody treatment for Alzheimer ’s, safety and benefit questions persist
In a packed San Francisco conference room with a celebratory atmosphere, upbeat company representatives and scientists yesterday presented detailed clinical trial data on the first Alzheimer’s treatment shown to clearly, albeit modestly, slow the disease’s normal cognitive decline. The antibody therapy has buoyed a field marked by decades of failures. Now, it appears to be on the cusp of being greenlit by the U.S. Food and Drug Administration (FDA). Yet other researchers warn of potential risks, including brain swelling and brain hemorrhages that were linked to the recently disclosed deaths of two trial participants wh...
Source: Science of Aging Knowledge Environment - December 1, 2022 Category: Geriatrics Source Type: research
Why Acupuncture Is Going Mainstream in Medicine
When the opioid addiction crisis began to surge in the U.S. about a decade ago, Dr. Medhat Mikhael spent a lot of time talking to his patients about other ways to heal pain besides opioids, from other types of medications to alternative treatments.
As a pain management specialist at MemorialCare Orange Coast Medical Center in Fountain Valley, Calif., he didn’t anticipate leaving behind the short-term use of opioids altogether, since they work so well for post-surgical pain. But he wanted to recommend a remedy that was safer and still effective.
That turned out to be acupuncture.
“Like any treatment, acupuncture...
Source: TIME: Health - April 29, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate medicine Source Type: news
Hospice Composition Based on Diagnosis is Associated with Caregiver-Reported Quality Measures
Conclusion: Hospices that cared for a greater proportion of dementia and stroke patients had poorer scores on caregiver-reported quality measures. These findings support efforts to identify mechanisms underlying these differences and to design strategies to ensure optimal outcomes for hospice patients regardless of diagnosis.PMID:35442840 | DOI:10.1177/10499091221088497
Source: The American Journal of Hospice and Palliative Care - April 20, 2022 Category: Palliative Care Authors: Sulaiman Alshakhs Elisabeth Sweet Elizabeth Luth M C Reid Charles R Henderson Veerawat Phongtankuel Source Type: research
